NTHi Virulence Gene Targeting for Otitis Media Vaccine Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to managing and preventing otitis media (OM), particularly caused by non-typeable Haemophilus influenzae (NTHi), are inadequate due to a lack of understanding of the pathogenesis and limited effective vaccines, with existing vaccines showing disappointing coverage and the invasive nature of surgical interventions.
Innovation Solution
The identification and characterization of the genomic sequence of NTHi strain 86-028NP and the polypeptides encoded by it, along with the development of methods for detecting NTHi bacteria and eliciting an immune response using specific antibodies and vaccines targeting upregulated genes such as hisB, lppB, sapA, and others, to treat and prevent OM.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotic therapy is used to treat otitis media, then bacterial infection is controlled, but antibiotic-resistant bacteria emerge
Solution Approach 1:
The patent extracts and identifies specific virulence genes (hif, lpf, lpt, lkp) and their encoded proteins as separate therapeutic targets. By isolating these specific pathogenic factors from the whole bacterium, the invention enables targeted intervention that eliminates the need for broad-spectrum antibiotics, thereby preventing resistance development while maintaining effective infection control.
Solution Approach 2:
The patent changes the therapeutic parameter from non-specific antibiotic application to specific gene/protein targeting. By identifying and targeting particular virulence factors (hif pilus, lpf fimbriae, lpt porin, lkp protein) with monoclonal antibodies or vaccines, the treatment mechanism shifts from general bacterial killing to precise neutralization of pathogenic functions, avoiding selective pressure for resistance.
2Ease of operation
If tympanostomy tubes are inserted to drain middle ear effusions, then pain is relieved and infection is cleared, but invasive surgical risks increase
Solution Approach 1:
The patent applies preliminary action by administering vaccines or monoclonal antibodies against NTHi virulence factors before infection establishes or progresses to chronic stages requiring surgery. By preventing infection upfront through targeted immunization, the need for invasive tube placement is avoided. The patent specifically identifies preventive vaccination as a strategy to eliminate surgical intervention.
Solution Approach 2:
The patent introduces monoclonal antibodies and vaccine-induced antibodies as intermediary substances that mediate protection against NTHi infection. These antibodies serve as biological intermediaries that neutralize virulence factors (hif, lpf, lpt, lkp) and prevent infection, replacing the need for mechanical surgical intervention with a biochemical protective mechanism.
3Reliability
If existing vaccines are used against NTHi, then some protection is provided, but coverage is disappointing and ineffective for chronic OM
Solution Approach 1:
The patent segments the NTHi bacterium into its critical virulence components (hif, lpf, lpt, lkp genes and their protein products) and develops targeted vaccines and monoclonal antibodies against each segment. This segmentation allows for precise targeting of specific pathogenic mechanisms rather than relying on whole-cell or capsule-based vaccines, improving both efficacy and adaptability across different disease stages including chronic OM.
Solution Approach 2:
The patent changes the vaccine target parameter from traditional capsular antigens or whole-cell preparations to specific virulence factor proteins (hif pilus protein, lpf fimbrial proteins, lpt porin, lkp outer membrane protein). This parameter change enables the vaccine to target essential virulence functions that are conserved across NTHi strains and critical for both acute and chronic disease, thereby improving coverage and effectiveness.
Data Source
AI summary
The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.